Ameya Chavan

Employment

• Evidera Inc Research Associate III
  2017 - Present

Education

• University of Maryland MS Information Systems
  2016 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA
  PharmacoEconomics 2022 DOI: 10.1007/s40273-022-01181-3
  +Save
• The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
  Neurology and Therapy 2022 DOI: 10.1007/s40120-022-00373-5
  +Save
• Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
  Neurology and Therapy 2022 DOI: 10.1007/s40120-022-00350-y
  +Save
• EPR22-119: Cost-Effectiveness of Multi-Cancer Early Detection (MCED) Test in Subgroups With Smoking History or Obesity
  Journal of the National Comprehensive Cancer Network 2022 DOI: 10.6004/jnccn.2021.7244
  +Save
• POSB44 Drivers of Value-Based Price (VBP) for a Multi-Cancer Early Detection (MCED) Test
  Value in Health 2022 DOI: 10.1016/j.jval.2021.11.317
  +Save
• Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia
  Journal of Medical Economics 2021 DOI: 10.1080/13696998.2020.1867443
  +Save
• Modeling long-term health and economic implications of new treatment strategies for Parkinson’s disease: an individual patient simulation study
  Journal of Market Access & Health Policy 2021 DOI: 10.1080/20016689.2021.1922163
  +Save
• PND57 Cost-Effectiveness Analysis of a Hypothetical Disease Modifying Therapy for Parkinson's Disease
  Value in Health 2020 DOI: 10.1016/j.jval.2020.08.1382
  +Save
• Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis
  Advances in Therapy 2020 DOI: 10.1007/s12325-020-01426-7
  +Save
• PND82 CONDUCTING CLINICAL TRIAL SIMULATION TO STUDY HETEROGENEITY OF TRIAL OUTCOMES IN AMYLOID-MODIFYING DRUGS
  Value in Health 2020 DOI: 10.1016/j.jval.2020.04.974
  +Save